Intercept Pharmaceuticals (ICPT) IPO Trades 26% Higher

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

The IPO for Intercept Pharmaceuticals, Inc., (Nasdaq: ICPT) opened for trading earlier at $19.40 after pricing 5,000,000 shares at $15, the high end of the expected $13-$15 range. Shares currently trade at $18.87.

BofA Merrill Lynch is acting as sole book-running manager for the offering.
BMO Capital Markets is acting as lead manager and Needham & Company, LLC, Wedbush PacGrow Life Sciences and ThinkEquity LLC are acting as co-managers

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR).

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
• Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea

Create E-mail Alert Related Categories

IPOs

Related Entities

Merrill Lynch, Needham & Company, Bank of America, ThinkEquity, BMO Capital

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?